Unknown Analyst's questions to Resmed Inc (RMD) leadership • Q2 2025
Question
An analyst from Goldman Sachs asked about the strong U.S. device growth and whether the impact from GLP-1 drugs is already being reflected in the numbers or if it's expected to be a future driver.
Answer
Executive Michael Farrell stated that while device growth was very strong, he believes there is not yet a material impact from the new Zepbound indication for sleep apnea. He characterized the current phase as the 'very early innings,' expecting a gradual increase in patient flow over the next 1 to 5 quarters with a durable impact over 1 to 5 years as physician education and consumer advertising ramp up.